Evaluation of the antineoplastic activity of mitoxantrone-L-carnitine combination therapy on an experimental solid form of ehrlich tumour in mice.
We have commenced a series of experiments to evaluate the effect of carnitine derivatives on the antineoplastic activity of mitoxantrone (MX) on various animal cancers. This report describes the therapeutic effect of MX in combination with l-carnitine (LCAR) on the growth of a solid form of Ehrlich tumour inoculated into mice. LCAR was administered subcutaneously at doses of either 200 or 100mgkg(-1) on day 6 and 13 after tumour inoculation, 1h prior to the treatment with MX. Mitoxantrone was administered intravenously at doses of 3 or 6mgkg(-1). We found that LCAR had no potentiating effect on the efficacy of MX, in terms of either slowing tumour growth or increasing the survival of mice. Nevertheless, therapeutic effects can be assumed at higher doses of both drugs based on values calculated from an index of relative hazards.
Niang
M
M
Department of Medical Biochemistry, Faculty of Medicine in Hradec Králové, Charles University in Prague, Simkova 870, 500 38 Hradec Králové, Czech Republic. niang@lfhk.cuni.cz
Melka
M
M
Stoklasová
A
A
Cerman
J
J
Tomsík
P
P
D000465:Algorithms; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy* / Q000473:pathology; D002331:Carnitine / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D051379:Mice; D008942:Mitoxantrone / Q000627:therapeutic use*; D013534:Survival
D000970:Antineoplastic Agents; D004338:Drug Combinations; D008942:Mitoxantrone; D002331:Carnitine